ReviewFrontiers in cell and developmental biology2025
Research progress of stem cells in the treatment of atherosclerosis.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Programmed Cell Death of Endothelial Cells in Ischemic Heart Disease: Mechanism and Potential Cell and Gene Therapeutic Prospects.Bioengineering (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Atherosclerosis (AS) is the primary pathological basis for the disability and mortality rates of global cardiovascular diseases. Its core characteristics are abnormal deposition of blood vessel wall lipids, chronic inflammatory activation, and vascular structural remodeling, which ultimately lead to acute cardiovascular and cerebral vascular events such as coronary heart disease and cerebral infarction. Existing treatment methods, such as statins and interventional interventions, can only delay disease progression and cannot reverse the pathological damage to blood vessels that has already occurred. Stem cells provide a novel strategy for the targeted therapy of AS due to their multi-directional differentiation potential, immune regulatory ability, and tissue repair properties. This review systematically reviews the research progress of stem cells in the treatment of AS in recent years, focusing on the mechanism of the main cell types such as mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and endothelial progenitor cells (EPCs), including regulating lipid metabolism, inhibiting inflammatory reaction, repairing vascular endothelium, and stabilizing atherosclerotic plaque. This study summarizes the key evidence from animal experiments and clinical trials in 2023-2025; analyzes core challenges such as low homing efficiency, short survival time, and the risk of immune rejection of stem cells; and proposes optimization strategies such as gene modification, biomaterial carriers, and combination therapy. Finally, the application prospects of single-cell sequencing, organoid models, and precision delivery systems in promoting the clinical translation of stem cells are discussed, with specific implementation paths being supplemented: single-cell sequencing can analyze the heterogeneity of stem cells in the AS lesion microenvironment (e.g., subtype differentiation differences of MSCs under hypoxic conditions) to screen high-activity stem cell subpopulations; vascular organoids constructed from patient-derived iPSCs can simulate the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.